Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Weinkove, R
McQuilten, ZK
Adler, J
Agar, MR
Blyth, E
Cheng, AC
Conyers, R
Haeusler, GM
Hardie, C
Jackson, C
Lane, SW
Middlemiss, T
Mollee, P
Mulligan, SP
Ritchie, D
Ruka, M
Solomon, B
Szer, J
Thursky, KA
Wood, EM
Worth, LJ
Yong, MK
Slavin, MA
Teh, BW
- Publisher:
- AMPCo
- Publication Type:
- Journal Article
- Citation:
- The Medical journal of Australia, 2020, 212, (10), pp. 481-489
- Issue Date:
- 2020-06
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
mja2.50607.pdf | Published version | 334.58 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Weinkove, R | |
dc.contributor.author | McQuilten, ZK | |
dc.contributor.author | Adler, J | |
dc.contributor.author | Agar, MR | |
dc.contributor.author | Blyth, E | |
dc.contributor.author | Cheng, AC | |
dc.contributor.author | Conyers, R | |
dc.contributor.author | Haeusler, GM | |
dc.contributor.author | Hardie, C | |
dc.contributor.author | Jackson, C | |
dc.contributor.author | Lane, SW | |
dc.contributor.author | Middlemiss, T | |
dc.contributor.author | Mollee, P | |
dc.contributor.author | Mulligan, SP | |
dc.contributor.author | Ritchie, D | |
dc.contributor.author | Ruka, M | |
dc.contributor.author | Solomon, B | |
dc.contributor.author | Szer, J | |
dc.contributor.author | Thursky, KA | |
dc.contributor.author | Wood, EM | |
dc.contributor.author | Worth, LJ | |
dc.contributor.author | Yong, MK | |
dc.contributor.author | Slavin, MA | |
dc.contributor.author | Teh, BW | |
dc.date.accessioned | 2020-08-24T01:55:32Z | |
dc.date.available | 2020-08-24T01:55:32Z | |
dc.date.issued | 2020-06 | |
dc.identifier.citation | The Medical journal of Australia, 2020, 212, (10), pp. 481-489 | |
dc.identifier.issn | 0025-729X | |
dc.identifier.issn | 1326-5377 | |
dc.identifier.uri | http://hdl.handle.net/10453/142294 | |
dc.description.abstract | INTRODUCTION:A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS:During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT:This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY:Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | AMPCo | |
dc.relation.ispartof | The Medical journal of Australia | |
dc.relation.isbasedon | 10.5694/mja2.50607 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences | |
dc.subject.classification | General & Internal Medicine | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Hematologic Diseases | |
dc.subject.mesh | Consensus | |
dc.subject.mesh | Hematology | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Australia | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Practice Guidelines as Topic | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Hematologic Diseases | |
dc.subject.mesh | Consensus | |
dc.subject.mesh | Hematology | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Australia | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Practice Guidelines as Topic | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | Australia | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | Consensus | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | Hematologic Diseases | |
dc.subject.mesh | Hematology | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | Practice Guidelines as Topic | |
dc.title | Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. | |
dc.type | Journal Article | |
utslib.citation.volume | 212 | |
utslib.location.activity | Australia | |
utslib.for | 11 Medical and Health Sciences | |
utslib.for | 17 Psychology and Cognitive Sciences | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/IMPACCT | |
pubs.organisational-group | /University of Technology Sydney | |
utslib.copyright.status | closed_access | * |
pubs.consider-herdc | false | |
dc.date.updated | 2020-08-24T01:55:28Z | |
pubs.issue | 10 | |
pubs.publication-status | Published | |
pubs.volume | 212 | |
utslib.citation.issue | 10 |
Abstract:
INTRODUCTION:A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS:During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT:This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY:Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph